Wide Neck Bifurcation Intracranial Aneurysms Clinical Trial
— WEB PASOfficial title:
Post-Approval Study - Post-Market Surveillance Study to Evaluate the Long-Term Safety and Effectiveness of the WEB Device
Verified date | November 2022 |
Source | Microvention-Terumo, Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
A prospective, multicenter, single arm, interventional study. The target patient population for this study are adult subjects with WNBAs of the anterior and posterior intracranial circulation. The primary effectiveness outcome of the study is adequate intracranial aneurysm occlusion on the 1 year angiogram as adjudicated by a core laboratory.
Status | Recruiting |
Enrollment | 180 |
Est. completion date | December 2029 |
Est. primary completion date | December 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Key Inclusion Criteria: - Patient must be = 18 at the time of screening - Patient must have a single ruptured or unruptured IA requiring treatment - Patient must sign and date an IRN approved written informed consent prior to initiation of any study procedures Key Exclusion Criteria: - Patient has an IA with characteristics unsuitable for endovascular treatment - Patient has conditions placing them at high risk for ischemic stroke or has exhibited ischemic symptoms such as transient ischemic attacks, minor strokes, or stroke-in-evolution within the prior 30 days - Patient has had an SAH from a non-index IA or other intracranial hemorrhage within 90 days - Patient index IA was previously treated - Patient is pregnant |
Country | Name | City | State |
---|---|---|---|
United States | Albany Medical Center | Albany | New York |
United States | West Virginia University | Morgantown | West Virginia |
Lead Sponsor | Collaborator |
---|---|
Microvention-Terumo, Inc. |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Key Effectiveness Outcome | Proportion of subjects with adequate aneurysm occlusion at one year after treatment. | 12 Months | |
Primary | Key Safety Outcome | Proportion of subjects with death of any nonaccidental cause or any major stroke* within the first 30 days after treatment or major ipsilateral stroke or death due to neurologic cause from day 31 to the 1 year after treatment | 12 Months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT03207087 -
The WEB®-IT China Clinical Study
|
N/A | |
Active, not recruiting |
NCT02191618 -
The WEB-IT Clinical Study
|
N/A |